The aims and objectives of the Tissue Core are as follows: 1) To receive, process and store blood samples in an efficient, and organized manner from CLL patients that have been diagnosed at various sites across the country. The first step will be to evaluate the suitability of the patient, collecting, testing, processing, packaging, labeling, and storing the tissue. The second step will be the distribution of the tissue to various sites for additional studies. In addition, the Tissue Core will assure accurate quality control, record keeping, and data management. Approximately 2,000 samples will be collected per year. These samples will be collected at a number of sites nationally using a uniform procedure. 2) To provide a central repository for CLL blood samples with basic minimum data information. When the samples are received by the Tissue Core, they will be assigned a unique patient identifier number and logged into a database. The sample will then be processed and viably store for future use. 3) To make the viably frozen samples readily available to other investigators across the country for future research studies. Investigators studying CLL will be able to request frozen vials by submitting the number and type of samples required and an outline of the proposed study. The approved investigators will sign an agreement regarding biohazards and commercial use of the tissue. 4) To perform basic panel of phenotypic and genetic tests on these CLL samples in a longitudinal manner pre and post therapy. The initial basic minimum set of tests that will be conducted on each patient sample will include: A- immunophenotyping analysis (Flow cytometry) to identify specific surface markers associated with CLL and immune activation, B- identification of the expressed Ig VH gene subgroup (AN-CR-ELISA), C- cytogenetic analysis to identify chromosomal abnormalities and karyotypic complexity, D- minimal residual disease testing (PCR to detect IgH rearrangements), E- microsatellite testing, a sensitive PCR technique used to screen for loss of heterozygosity that may escape conventional cytogenetic analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA081534-01
Application #
6259057
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-05-01
Project End
2000-04-30
Budget Start
Budget End
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Wu, Bainan; Barile, Elisa; De, Surya K et al. (2015) High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists. Curr Top Med Chem 15:2032-42
Wu, Bainan; Wang, Si; De, Surya K et al. (2015) Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem Biol 22:876-887
Lamothe, Betty; Cervantes-Gomez, Fabiola; Sivina, Mariela et al. (2015) Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood 125:407-10
Veronese, A; Pepe, F; Chiacchia, J et al. (2015) Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia 29:86-95
Maji, Santanu; Samal, Sabindra K; Pattanaik, Laxmipriya et al. (2015) Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget 6:16623-37
Laganà, Alessandro; Acunzo, Mario; Romano, Giulia et al. (2014) miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Res 42:5416-25
McClanahan, Fabienne; Gribben, John (2014) Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies? Hematol Oncol Clin North Am 28:1055-71
Barile, Elisa; De, Surya K; Feng, Yongmei et al. (2013) Synthesis and SAR studies of dual AKT/NF-?B inhibitors against melanoma. Chem Biol Drug Des 82:520-533
Vamos, Mitchell; Welsh, Kate; Finlay, Darren et al. (2013) Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. ACS Chem Biol 8:725-32
Hudson, Robert S; Yi, Ming; Volfovsky, Natalia et al. (2013) Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. Mol Cancer 12:13

Showing the most recent 10 out of 46 publications